drugset
drugset / Trial / NCT03433378

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

NCT03433378 ↗

Phase 0 Completed 700 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.

Timeline

Start
2017-08-04
Primary completion
2018-01-26
Completion
2018-01-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tretinoin Small molecule 0.05 % —

Indications

acne